137106-06-0

Basic information

• Product Name: 1-benzyl-3(S)-hydroxy-4(S)-methylpyrrolidine
• CAS NO: 137106-06-0
• Molecular Weight: 191.273
• Mol File: 137106-06-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-benzyl-3(S)-hydroxy-4(S)-methylpyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-3(S)-hydroxy-4(S)-methylpyrrolidine(137106-06-0)
• EPA Substance Registry System: 1-benzyl-3(S)-hydroxy-4(S)-methylpyrrolidine(137106-06-0)

Safety Data

• Hazardous Substances Data: 137106-06-0(Hazardous Substances Data)

Upstream product

• 676-58-4 methylmagnesium chloride 
• 75390-09-9 3-benzyl-6-oxa-3-azabicyclo[3.1.0]-hexane 

Downstream Products

• 137172-64-6 (3R,4S)-N-benzyl-3-hydroxy-4-methylpyrrolidine 
• 137172-65-7 (3S,4R)-N-benzyl-3-hydroxy-4-methylpyrrolidine 
• 69498-29-9 (-)-(3R)-N-benzyl-3-methylpyrrolidine 
• 144043-21-0 N-benzyl-3-<<(methylthio)thiocarbonyl>oxy>-4-methylpyrrolidine 
• 137172-68-0 (3S,4R)-N-benzyl-3-azido-4-methylpyrrolidine 
• 137106-07-1 (3S,4S)-N-benzyl-3-azido-4-methylpyrrolidine 
• 137172-66-8 (3R,4R)-N-benzyl-3-azido-4-methylpyrrolidine 
• 137172-67-9 (3R,4S)-N-benzyl-3-azido-4-methylpyrrolidine 
• 137106-08-2 Toluene-4-sulfonic acid (3S,4R)-1-benzyl-4-methyl-pyrrolidin-3-yl ester 
• 137106-08-2 Toluene-4-sulfonic acid (3R,4S)-1-benzyl-4-methyl-pyrrolidin-3-yl ester 

Relevant articles and documents

Fluoronaphthyridines and -quinolines as Antibacterial Agents. 5. Synthesis and Antimicrobial Activity of Chiral 1-tert-Butyl-6-fluoro-7-substituted-naphthyridones

A series of novel 7-substituted-1-tert-butyl-6-fluoronaphthyridone-3-carboxylic acids has been prepared.These derivatives are characterized by chiral aminopyrrolidine substituents at the 7 position.In this paper we report the full details of the asymmetric synthesis of this series of compounds.Structure-activity relationship studies indicate that the absolute stereochemistry at the asymmetric centers of the pyrrolidine ring is critical for maintaining good activity.Compounds 60 and 61 (3-amino-4-methylpyrrolidine enantiomers) were selected for preclinical evaluation.